Pharmaceuticals, Biotechnology and Life Sciences
Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover.
Teva Pharmaceutical Industries on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
GlaxoSmithKline’s new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.
Three of Europe’s top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi <SASY.PA> and Roche <ROG.S> likely to win approvals for two new products, while GlaxoSmithKline <GSK.L> braces for a potential generic rival.
A major research has been initiated, which will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.
GSK Consumer Healthcare has launched parodontax, a new daily toothpaste that is clinically proven to help control bleeding gums, in U.S.
Patients with eosinophilic inflammation that were treated with GSK’s mepolizumab Nucala as addition to the standard care, reached improvements in health and lung function compared to patients treated with placebo added to the standard care.
Vectura Group has reached a royalty cap on net sales of £9 million from selling GSK’s respiratory Ellipta products in 2016.
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
GlaxoSmithCline has posted net profit in the fourth quarter 2016 of £1,062 million and fully year £8,372, and turnover revenue growth of 6% with sales mounting to £27.9 billion, mainly driven by continued strong performance of new products.